Aurobindo Pharma Ltd receives USFDA Final Approval

This approval is Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. The product will be manufactured at Unit-IV of APL Healthcare, a wholly-owned subsidiary of theCompany and will be launched in Q3FY27. The approved product has an estimated market size of US$ 67 million for the twelve months ending August 2026, according to IQVIA MAT. Aurobindo Pharma now has a total of 599 ANDA approvals (574 final approvals and 25 tentative approvals) from USFDA. Perampanel Tablets are (i) indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older and (ii) indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. Opinion : This news will have positve impact on the stock price. Disclaimer : I do not hold this stock. THis is not a buy,sell or hold recommendation